- Home
- NBXG vs CDNA Comparison
NBXG vs CDNA Comparison
Compare NBXG & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- CDNA
- Stock Information
- Founded
- NBXG 2021
- CDNA 1998
- Country
- NBXG United States
- CDNA United States
- Employees
- NBXG N/A
- CDNA N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- CDNA Medical Specialities
- Sector
- NBXG Finance
- CDNA Health Care
- Exchange
- NBXG Nasdaq
- CDNA Nasdaq
- Market Cap
- NBXG 1.0B
- CDNA 1.1B
- IPO Year
- NBXG N/A
- CDNA 2014
- Fundamental
- Price
- NBXG $12.85
- CDNA $21.52
- Analyst Decision
- NBXG
- CDNA Buy
- Analyst Count
- NBXG 0
- CDNA 8
- Target Price
- NBXG N/A
- CDNA $27.17
- AVG Volume (30 Days)
- NBXG 243.7K
- CDNA 691.6K
- Earning Date
- NBXG 01-01-0001
- CDNA 02-26-2025
- Dividend Yield
- NBXG 10.25%
- CDNA N/A
- EPS Growth
- NBXG N/A
- CDNA N/A
- EPS
- NBXG N/A
- CDNA N/A
- Revenue
- NBXG N/A
- CDNA $312,775,000.00
- Revenue This Year
- NBXG N/A
- CDNA $19.85
- Revenue Next Year
- NBXG N/A
- CDNA $11.34
- P/E Ratio
- NBXG N/A
- CDNA N/A
- Revenue Growth
- NBXG N/A
- CDNA 5.26
- 52 Week Low
- NBXG $9.31
- CDNA $7.42
- 52 Week High
- NBXG $12.23
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- NBXG 43.47
- CDNA 41.67
- Support Level
- NBXG $12.69
- CDNA $20.35
- Resistance Level
- NBXG $13.07
- CDNA $21.68
- Average True Range (ATR)
- NBXG 0.21
- CDNA 1.13
- MACD
- NBXG -0.04
- CDNA -0.04
- Stochastic Oscillator
- NBXG 33.55
- CDNA 30.62
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.